Transcript
Page 1: CAR-T CELL-BASED IMMUNOTHERAPY BASIC PRINCIPLES

Copyright © 2018 Creative Biolabs. All Rights Reserved. Email: [email protected] Tel: 1-631-381-2994

CAR-T CELL-BASED IMMUNOTHERAPYBASIC PRINCIPLES

The basic design of CAR includes a tumor-associated antigen (TAA) binding region (usually scFv), an extracellular hinge region, a transmem-brane region and an intracel-lular signal. The first chimeric TCR was constructed by replacing the Vα and Vβ extra-cellular domains of the TCR chains. Single chain antibody links the CD3ζ for the first generation. Costimulatory molecule, such as CD28, has been engineered to the signal transduction region for the second generation. Another costimulatory molecule based on the second generation for the third generation has been engineered to the signal transduction region. The cytokines based on the second generation for the fourth generation has been engineered to the signal transduction region.

A dual CAR T cell expresses two separate CARs with differ-ent ligand binding targets. Dual CAR T cell activation requires co‑expression of both targets on the tumour. A conditional CAR T cell is by default unresponsive until the addition of a small molecule to complete the circuit. A tandem CAR T cell expresses a single CAR consisting of two linked scFvs that have differ-ent affinities. The physiologi-cal CAR consists of an antigen receptor and a CD3ζ intracel-lular signaling domain with/without a transmem-brane and a spacer region. The universal CAR utilizes biotin or anti-FITC scFv as targeting region fused with the trans-membrane domain. Marked CAR T cells express a CAR plus a tumour epitope to which an existing monoclonal antibody agent binds.

Creative BiolabsCAR/TCR-relatedProducts &Services

Evolution of CAR2

New CAR Models and Concepts3

Structural and Functional Basis of CAR1

Antigen-bindingregion (scFv)

Monoclonalantibody

VH

VH

VL

VL

TCR-CD3complex

Hinge region

Tumor cell

Anti-tumor signal Tumor antigen

T cell

γ ε α β ε δζζ

Transmembraneregion

Signal transductionregion

Cell activationCytotoxicity inductionCytokine productionCell survivalCell proliferation

CD8α CD4

CD28

Receptor& ligand

Additional smallmolecule

Avidin/anti-FITClabeled scFv Biotin/FITC Selection marker

Hinge

IgG1 sequences Co-stimulating ligandTransgene

Cytokine4-1BB

1989

1993

1998 2003 2004

2007

2009

CD3ζ

ClassicCAR

DualCAR

TandemCAR

PhysiologicalCAR

UniversalCAR

MarkedCAR

Seminal research1st-generation

2nd-generation3rd-generation

4th-generation

+1

2

+1

2

+1

2

+1

2

+1 2

ConditionalCAR

+1 2

γ ζζα βε ε δ

WHAT WE DO:Products:Diseases Associated AntigenCAR Vector SystemViral Particle CAR/TCR Development Kits

One-Stop CAR-T Therapy Development Services TCR Modified T Cell Development ServicesTCR-Like Antibody Services Dendritic Cell Vaccine Development ServicesBispecific TCR Development Service

Recommended